ASSET OVERVIEW
A closer look at the opportunity.
First-in-Class Opportunity
Oral, potent, and selective ATM kinase inhibitor (IC₅₀ = 0.42 nM) with >1,000-fold selectivity over other PIKK family members.
Synergistic Radiosensitizer & Chemosensitizer
Enhances efficacy of (1) Radiotherapy in NSCLC, glioma, and colon models;
(2) Chemotherapy (irinotecan) and PARP inhibitors; (3) EGFR-ADC (SYS6010) in NSCLC xenograft.
Robust PK, Safety & ADME
Favorable oral bioavailability and brain penetration; No hERG liability (IC₅₀ = 2.86 µM); Clean safety in rats and dogs (MTD ≥60–100 mg/kg); No abnormal CNS, cardiovascular, or respiratory findings.
Development Status
Ongoing Phase 1 clinical studies in multiple regions globally.
Strategic Fit
Strategic Fit for DDR, Radiotherapy, ADC & Solid Tumor Developers.
Source: existing JEA asset materials. These descriptions include historical development plans and sponsor-reported data; contact JEA for current status and supporting materials.
← Back to all opportunities